Wela Strategies, Inc. In8 Bio, Inc. Transaction History

Wela Strategies, Inc.

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 Apr 15, 2024	BUY	$0.95 - $1.69 $17,620 - $31,346	18,548 New	18,548 $21,000

344K

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $39M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

Get notified when there are updates to the investment portfolio of Wela Strategies, Inc., based on Form 13F filings with the SEC.

Stay updated on Wela Strategies, Inc. with notifications on news.